While President Joe Biden is trying to reduce the prices of medication in an effort to help Americans in an era categorized by soaring costs across the board, he’s facing pushback from some unlikely sources – his own party.
Democrats Clash Over Drug Price Negotiations
Drug prices have famously been high in the U.S., and Biden is trying to make that a thing of the past by using Medicare to slash prices. However, members of his own party are fighting against him.
Big Pharma Influence
A new report by Jacobin has shown that big pharma-backed Democrats are trying to keep drugs expensive, stop Biden’s negotiations, and protect the tax loopholes that keep these pharmaceutical companies profitable.
Report Findings
According to the report, Democratic Representatives Scott Peters, Wiley Nickel, Josh Gottheimer, and Donald Davis are all working together on bills that aim to stop Medicare’s ability to negotiate on price and roll back any previous price changes.
Pharmaceutical Lobbying
Pharmaceutical companies have lobbied these Democrats with over $300,000 in donations, as they have ties to states with major biotech or drug industry hubs.
Bills Could Undermine Biden’s Negotiation Efforts
If enacted, experts warn these bills could weaken Biden’s negotiation efforts, meaning high prices would remain the norm for lifesaving drugs. While Biden wants to expand Medicare negotiations to 500 drugs by 2034, these new bills would heavily limit that figure.
Balancing Profitability and Research Funding
Critics of Biden’s policies argue that drug negotiations stifle innovation and can deter companies from funding new experiments, especially in rare-disease research, which is often a risky investment.
Innovation Debate
However, experts argue that even with price negotiations, pharmaceutical companies still reap substantial profits, so the incentive is still there to innovate and develop complicated drugs.
Legal Challenges
Jacobin explains that pharmaceutical giants are resorting to legal action to stop drug price negotiations. Companies like Bristol Myers Squibb and Novartis are suing, claiming that Medicare negotiations infringe on their company’s constitutional rights.
Big Pharma Spending to Influence Legislation
Lobbying groups for big pharma spent $36 million last year advocating against the Inflation Reduction Act and for bills that would increase their profits.
Focusing on Drugs to Combat Rare Diseases
The Biotechnology Innovation Organization, which represents the biotech industry, specifically lobbied on bills like the ORPHAN Cures Act and MINI Act.
Orphan Drug Development
The Inflation Reduction Act aimed to support research on medicines for rare diseases by exempting “orphan drugs” (drugs for diseases that affect fewer than 200,000 people in the U.S.) from Medicare price negotiations, but only if these drugs cured a single rare disease.
This was done to keep the monetary incentive for companies to develop cures for these diseases.
Loophole Exploitation
However, a loophole in the Orphan Drug Act allows drug makers to retain tax incentives and other benefits even if their drugs are later approved for additional uses.
The ORPHAN Cures Act and Its Implications
Now, the proposed ORPHAN Cures Act seeks to change the Inflation Reduction Act to exclude orphan drugs entirely, regardless of the number of diseases they treat. The bill has garnered support from both Democrats and Republicans, including previously mentioned Representatives Peters, Nickel, Davis, and Gottheimer.
Campaign Contributions and Industry Ties
Peters, known for his ties to the pharmaceutical industry, has received significant campaign contributions from companies with ties to big pharma. He has previously faced criticism for successfully halting a 2021 House Bill that would have given the government power to negotiate on drug prices.
Criticism Surrounding Funding Sources
The majority of the outcry stemmed from an immediate $20,000 donation that was gifted to him from lobbyists, although critics also pointed out that there may have been a conflict of interest as his wife is CEO of an investment firm that has a stake in a pharmaceutical manufacturing company.
Defensive Position
For his part, Peters defended the lobbying, stating, “I’m not going to unilaterally disarm and defund my campaign so that Republicans can win. I just think that’s a dumb thing to do.”
MINI Act
The MINI Act, which was proposed by Democrat Nickel and backed by both Peters and Davis, is legislation that aims to extend the amount of time a “small-molecule drug” can be on the market before the government can negotiate its price. At the moment the government cannot request a price change on this category of drugs for seven years from creation, but lawmakers hope to increase it to eleven years.
Extending Market Exclusivity for Small-Molecule Drugs
Nickel argues that small-molecule drugs which utilize high-tech genetic technology, often used for rare diseases, require significant investment and risk and should have a longer period at a price dictated by Pharma companies in order to recoup investment.
Balancing Innovation and Investment
He emphasized that “When we incentivize innovation into one type of drug and not the other, we are hurting the potential for cures and treatments in certain areas medically” and stressed that the MINI act would push medical advancements in important drugs that are used by both pediatric and young-adult populations.
Pushing for MINI Act Support in Congress
According to the report, lobbyists have spent over $9 million in 2023 alone on pushing the MINI Act, with Nickel receiving at least $41,000.
Lawmakers Supporting Bills Limiting Biden’s Agenda
Other Democrats also received huge contributions from pharmaceutical firms in 2023, leading to many backing bills that would limit the scope of Biden’s aims.
21 States Where Squatters Can Legally Claim Your Property
Discover how squatters’ rights, or adverse possession, are more than just legal jargon—they’re stories of unexpected twists in the world of real estate. From sunny California to the historical landscapes of Pennsylvania, here’s how these laws could turn the tables on homeowners and squatters alike. 21 States Where Squatters Can Legally Claim Your Property
14 Things That Are Banned in the U.S. but Totally Fine Elsewhere
Ever feel like America’s rulebook was written by someone with a dartboard? Across the pond or down under, things get even wackier. Let’s take a walk on the wild side of global “Do’s” that are definite “Don’ts” in the Land of the Free. 14 Things That Are Banned in the U.S. but Totally Fine Elsewhere
25 American States Nobody Wants to Visit Anymore
Across the United States, some states capture the hearts and itineraries of many, while others remain quietly on the sidelines, overshadowed or misunderstood. These 25 states, facing what you might call a popularity crisis, are brimming with hidden wonders, cultural riches, and natural beauty, awaiting those willing to look beyond the usual tourist trails. 25 American States Nobody Wants to Visit Anymore
20 Foods That Are Cheaper to Eat Out Than Making at Home
In a world where convenience often wins, certain culinary delights come with a lower price tag when enjoyed at a restaurant rather than crafted in your own kitchen. Here are twenty foods that might save you both time and money when indulged in at your favorite eatery. 20 Foods That Are Cheaper to Eat out Than Making at Home
17 Things You’re Paying For, but You Don’t Have To
In the land of the free, there’s a price tag on everything, but savvy Americans know better than to open their wallets for just anything. Here are 17 expenses you’ve been shelling out for without realizing there’s a cheaper or even free alternative. 17 Things You’re Paying For, but You Don’t Have To
The post Biden’s Drug Price Plan Meets Opposition from Fellow Democrats first appeared on From Frugal to Free.
Featured Image Credit: Shutterstock / lev radin.
The content of this article is for informational purposes only and does not constitute or replace professional financial advice.
